The primary objective of this trial is to continue the provision of darunavir/ low-dose
ritonavir (DRV/rtv) to adult and pediatric patients who previously received DRV/rtv in the
clinical trials TMC114-C211, TMC114-C214, TMC114-TiDP31-C229 or in the pediatric trial
TMC114-TiDP29-C232 who continue to benefit from the use of DRV/rtv, in countries where DRV
is not commercially available for the subject, is not reimbursed, or cannot be accessed
through another source (e.g., access program, governmental program).